Drug Profile
Iodine-131-SGMIB anti-HER2 monoclonal antibody
Alternative Names: 131I-SGMIB anti-HER2-VHH1; [131I]-SGMIB Anti-HER2 VHH1; CAM-H2; CAM-H2-I131; Iodine-131-SGMIB anti-HER2 VHH1Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Camel-IDS
- Developer Precirix
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Immunomodulators; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Breast cancer; Gastric cancer; Oesophageal cancer
Most Recent Events
- 04 May 2021 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT04467515)
- 04 May 2021 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT04467515)
- 29 Apr 2021 Phase-I/II clinical trials in Oesophageal cancer (Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT04467515)